{
  "docId": "019dd923-5ca1-7489-b638-e62bea0762fa",
  "docSlug": "78005f3a3554aa50",
  "documentTitle": "Refueling Innovation Engine Vaccines",
  "authorId": "McKinsey",
  "authorName": "McKinsey",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.333,
  "pageNumber": 22,
  "pageCount": 40,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "industry_trends",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide uses a bar chart to illustrate the convergence of success rates between vaccines and biologics, supporting the argument that vaccines are becoming less attractive for investment compared to biologics.",
  "elementsJson": [
    "headline_text",
    "bar_chart_grouped",
    "bullet_list"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b638-e62bea0762fa/22",
  "deckHref": "/decks/019dd923-5ca1-7489-b638-e62bea0762fa",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b638-e62bea0762fa.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b638-e62bea0762fa#slide-22",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "The convergence of success rates in vaccines and biologics makes vaccines less attractive for investment",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd951-d3bb-700a-9da7-7d63bc6ecac2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.63,
        "x": 0.04,
        "y": 0.155
      },
      "kind": "chart",
      "text": "Success rate of products from Phase I to launch",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c77a9a8c-4770-4790-9d11-9a77890c47ed",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.29,
        "x": 0.68,
        "y": 0.155
      },
      "kind": "list",
      "text": "Vaccines have peak revenues of up to low digit billion (e.g. the blockbuster Prevnar13 - $6B, Gardasil - $2B)\nBiologics conversely can have peak revenues of up to double digit billion (e.g. Humira $19B, Enbrel $13B)\nThe convergence of success rates in vaccines and biologics makes vaccines less attractive for investment",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "759e90e4-64d6-4df6-8053-9e01e8f4df28",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Success rate: 16%",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd951-d3bb-700a-9da7-8308d8e10c23",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.03,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "SOURCE: Pharmaprojects 2013",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b9dca1b-324c-4ecc-9425-c10940f39e1a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.94,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Relative vaccine economics have been changing, with lower returns on investment as success rates converge with biologics",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6b0e099e-cb83-4cf1-8689-01edf841e6f2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [
    {
      "metricRaw": "Success rate",
      "numberRaw": "16%",
      "numberKind": "percent",
      "actionTitle": "Relative vaccine economics have been changing, with lower returns on investment as success rates converge with biologics",
      "calloutText": "The convergence of success rates in vaccines and biologics makes vaccines less attractive for investment",
      "numberScale": null,
      "numberValue": 16,
      "metricFamily": "rate_catchall",
      "numberCurrency": null
    }
  ],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}